[Predictive factors of response to buprenorphine in the substitutive treatment of heroin addicts. Results of a multicenter study of 73 patients].
OBJECTIVE
Buprenorphine has a partial morphine-agonist pharmacological profile. It is proposed as alternative to methadone in opiate drug addicts with greater safety of use and less cost in terms of public health. The aim of this study was to determine the clinical factors of response to this molecule.


METHODS
The study was conducted in 73 patients treated for 3 months with adaptable doses. Mean dose was 8.5 mg/d (range: 3 to 16 mg/d). Response to treatment was defined as: still in the study at 3 months and absence of opiates in 75% of urinary samples over the past month.


RESULTS
Forty-eight patients responded and 25 did not. The determinating clinical variables of response were: opiate drug addiction less than 10 years, high score on the Addiction Severity Index (ASI), absence of depression according to the Minnesota Multiphasic Personality Inventory (MMPI) and low rate of disinhibition on Zukerman's sensation seeking scale. Conversely, the dose of buprenorphine within the limits specified in the Marketing Authorisation did not intervene in the response.


CONCLUSIONS
In view of its partial agonist effect, administration of buprenorphine must be reserved for patients addicted to opiates for less than 10 years, non-depressive and with low disinhibition on Zukerman's scale.
Laqueille
X
X
Service des Professeurs LOO et OLIE, Centre Hospitalier Sainte-Anne, 1 rue Cabanis, F75014 Paris, Université Paris V René Descartes.
Poirier
M F
MF
Jalfre
V
V
Bourdel
M C
MC
Willard
D
D
Olié
J P
JP
D000328:Adult; D002047:Buprenorphine / Q000627:therapeutic use*; D005260:Female; D006556:Heroin Dependence / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009294:Narcotics / Q000627:therapeutic use*; D011379:Prognosis; D011446:Prospective Studies
D009294:Narcotics; D002047:Buprenorphine